文献速递淋巴瘤

帕博利珠单抗联合伏立诺他诱导既往PD-1阻断难治的霍奇金淋巴瘤患者缓解

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade.
PubMed 文献 · Blood · 2023-01-01

这项1期研究在复发/难治经典型霍奇金淋巴瘤等患者中评估帕博利珠单抗联合伏立诺他,报告经典型霍奇金淋巴瘤结果:32例可评估,78%既往接受抗PD-1治疗、56%为PD-1难治;总缓解率72%、完全缓解率34%,PD-1难治者(n=18)总缓解率56%、完全缓解率11%。

要点

  • 推荐2期剂量为伏立诺他200mg每日两次联合帕博利珠单抗200mg每3周一次。
  • 32例经典型霍奇金淋巴瘤患者总缓解率72%、完全缓解率34%。
  • 既往PD-1阻断难治者(n=18)总缓解率56%、完全缓解率11%。

核心结论

  • 帕博利珠单抗联合伏立诺他耐受性良好,在复发/难治经典型霍奇金淋巴瘤中包括抗PD-1难治性疾病中获得较高的总缓解率。

研究设计与样本

  • 1期研究,剂量递增队列设2个剂量水平,随后在推荐2期剂量下扩展,21天为一周期。
  • 纳入接受过≥1线既往治疗且不适合移植的复发/难治经典型霍奇金淋巴瘤成人患者,共32例,其中30例在剂量水平2(推荐2期剂量)。
  • 伏立诺他100mg每日两次(剂量水平1)或200mg每日两次(剂量水平2)口服,第1至5天和第8至12天给药;所有患者接受帕博利珠单抗200mg静脉注射每3周一次。
  • 主要终点为安全性和推荐2期剂量的确定。

主要发现

  • 32例经典型霍奇金淋巴瘤患者中,78%既往接受过抗程序性细胞死亡1(抗PD-1)治疗,56%为PD-1难治。
  • ≥3级不良事件包括高血压(9%)、中性粒细胞减少(9%)、低磷血症(9%)、血小板减少(6%)和淋巴细胞减少(6%)。
  • 免疫相关不良事件包括1或2级甲状腺炎(13%)、1级皮疹(6%)和3级食管炎/十二指肠炎(3%)。
  • 总缓解率为72%,完全缓解率为34%。
  • 既往PD-1阻断难治的患者(n=18)总缓解率和完全缓解率分别为56%和11%。

关键数值与推荐

  • 推荐2期剂量为伏立诺他200mg每日两次(剂量水平2)联合帕博利珠单抗200mg静脉注射每3周一次。
  • 总缓解率72%,完全缓解率34%(32例经典型霍奇金淋巴瘤患者)。
  • 既往PD-1阻断难治患者(n=18)总缓解率56%,完全缓解率11%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This phase 1 study evaluated the addition of vorinostat to pembrolizumab in patients with relapsed/refractory (RR) classical Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma, and follicular lymphoma. We report the results in cases of cHL. Adult patients with RR cHL who had received ≥1 prior lines of therapy and were ineligible for transplantation were treated in a dose-escalation cohort with 2 dose levels (DLs) and then on an expansion cohort at the recommended phase 2 dose (RP2D) in 21-day cycles. Vorinostat 100 mg twice a day (DL1) and 200 mg twice a day (DL2) was administered orally from days 1 to 5 and 8 to 12; all patients received pembrolizumab 200 mg IV every 3 weeks. The primary end point was safety and determination of RP2D. In total, 32 patients with cHL were enrolled, including 30 at DL2 (RP2D); 78% had received prior anti-programmed cell death 1 (anti-PD-1) therapy, and 56% were PD-1 refractory. Grade ≥3 adverse events (AEs) included hypertension (9%), neutropenia (9%), hypophosphatemia (9%), thrombocytopenia (6%), and lymphopenia (6%). Immune-related AEs included grade 1 or 2 thyroiditis (13%), grade 1 rash (6%), and grade 3 esophagitis/duodenitis (3%). The overall response rate (ORR) was 72% and complete response (CR) rate was 34%. Patients refractory to prior PD-1 blockade (n = 18) had ORR and CR rates of 56% and 11%, respectively. Pembrolizumab and vorinostat was well tolerated with a high ORR rate in RR cHL including in anti-PD-1-refractory disease. This trial was registered at www.clinicaltrials.gov as #NCT03150329.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Mei M, Chen L, Godfrey J, et al. Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade. Blood. 2023. PMID: 37339586. doi:10.1182/blood.2023020485

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。